CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest

CERO THERAPEUTICS HOLDINGS, INC.

Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.
Note matures April 27, 2027; bears 10% annual interest; convertible at lower of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
Conversion subject to 4.99% beneficial ownership limitation; resale registration required on Form S-1 or S-3.
Issuance exempt under Section 4(a)(2) and Rule 506(b); accredited investor only.

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.